FindTrial
Sign In

Association of tenofovir disoproxil fumarate use with bone-related adverse events in chronic hepatitis B: a systematic review and meta-analysis

Association of tenofovir disoproxil fumarate use with bone-related adverse events in chronic hepatitis B: a systematic review and meta-analysis - Association of tenofovir disoproxil fumarate use with bone-related adverse events in chronic hepatitis B: a systematic review and meta-analysis

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000051192
Enrollment
Unknown
Registered
2023-05-30
Start date
2023-05-30
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with chronic hepatitis B using tenofovir disoproxil fumarate

Interventions

None listed

Sponsors

Hyogo Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Chronic HBV infection (HBsAg positive for more than 6 months) Serum ALT level greater than 60 U/L (men) or 38 U/L (women) and less than 10 times the upper limit of normal (ULN) at screening Estimated creatinine clearance (CLCr) above 50 mL/min

Exclusion criteria

Exclusion criteria: Pregnant women, women who are breast feeding or who believe they may wish to become pregnant during the course of the study Coinfection with HCV, HIV or HDV

Design outcomes

Primary

MeasureTime frame
Frequency of fractures Change in bone density before and after drug use Change in percentage of patients with T-score below -2.5 before and after drug use—

Countries

Japan

Contacts

Public ContactSho Masago

Hyogo Medical University School of Pharmacy

dph2303@hyo-med.ac.jp078-304-3000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026